The combination of translatable in-vitro and in-vivo assays, coupled with expertise in immunology and oncology helps facilitate the progression of novel oncology therapeutics from hit identification to investigational new drug submission.
Martin O’Rourke, PhD
Advertisement
Martin O’Rourke, PhD, is senior director, Oncology In-Vitro Biosciences, Integrated Drug Discovery at Charles River Laboratories.
Articles by Martin O’Rourke, PhD
Advertisement
Latest Updated Articles
- The Power of In Vitro Assays in Immuno-Oncology
Published: May 23rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
2
AI and Human Collaboration Essential for Bio/pharma Innovation
3
Sustainability and Stability in Excipients
4
Centralizing AI Strategy, Ensuring Process Integrity, and Balancing Quick Wins with Long-Term Drug Design in Bio/pharma
5
